samedan logo
 
 
spacer
home > pmps > spring 2017 > paper chase
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Paper Chase

If you were to compare the 21st century pharmaceutical and biotechnology sector with how it started life, you would barely recognise it as the same industry. Its roots go back to when apothecaries and pharmacies offered traditional – but often hit-and-miss – treatments based on old wives’ tales and word of mouth. Today, it is built on a variety of scientific expertise and innovative technologies that are changing the way in which medicines are manufactured. However, despite these advances, many companies are still reliant on processes that are supported by paper documentation and printed forms.

Information scientists have discussed and envisioned the concept of a paperless society – a world in which paper communications and documents are replaced by electronic storage – since the late 1970s, but it is only in recent years that this has become a standard business objective. In the past decade, organisations from almost every industry have committed to becoming ‘greener’, often starting by reducing or eliminating paper-based processes in favour of a digital approach.

By taking advantage of the solutions that today’s technology offers, firms are able to reduce errors, collect accurate records and streamline operations.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Robert Harrison leads the Pharmaceutical Division at COPADATA. With over 20 years of international experience, he has served in varying management and engineering roles across industry and research, gaining his BSc in Electronic Engineering while working at CERN, Switzerland. Robert is currently responsible for driving strategy, technology development, global growth and worldwide performance of zenon technology in the life sciences sector.
spacer
Robert Harrison
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cerba Research and ACT Genomics Announce Strategic Joint Venture — CerbACT Asia

This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.
More info >>

White Papers

Antibody Internalization: Advanced Flow Cytometry and Live-Cell Analysis Give Rich Insights During Antibody Profiling

Sartorius Group

The natural characteristics of antibodies, such as high binding affinity, specificity to a wide variety of targets, and good stability, make them ideal therapeutic candidates for many diseases. Monoclonal antibodies (mAbs), in particular, deliver promising therapeutic results in several different disease areas, such as autoimmunity, oncology, and chronic inflammation. Researchers’ abilities to improve the breadth of antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody design techniques create the need for new screening methods so that lead candidates can be quickly and effectively identified as early in the development process as possible.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement